Stock Scorecard



Stock Summary for Icon Plc (ICLR) - $182.61 as of 1/16/2026 10:00:40 PM EST

Total Score

10 out of 30

Safety Score

55 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ICLR

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ICLR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ICLR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ICLR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ICLR (55 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 7
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ICLR

Icon Plc $ICLR Stake Boosted by Stephens Investment Management Group LLC 1/17/2026 12:27:00 PM
SG Americas Securities LLC Sells 7,740 Shares of Icon Plc $ICLR 1/17/2026 10:27:00 AM
Trinity Street Asset Management LLP Has $152.42 Million Stock Position in Icon Plc $ICLR 1/16/2026 12:29:00 PM
Does ICON (ICLR) Face a Deeper Credibility Test as Disclosure Risks Draw Fresh Scrutiny? 1/16/2026 8:27:00 AM
Walter Public Investments Inc. Decreases Stake in Icon Plc $ICLR 1/15/2026 1:28:00 PM
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $217 1/10/2026 7:28:00 AM
Rothschild Investment LLC Purchases New Position in Icon Plc $ICLR 1/9/2026 2:15:00 PM
Truist Financial Downgrades Icon PLC(ICLR.US) to Hold Rating, Announces Target Price $222 1/9/2026 6:14:00 AM
Icon Plc $ICLR Shares Bought by Tributary Capital Management LLC 1/8/2026 1:11:00 PM
Truist Securities downgrades ICON stock to Hold on growth concerns 1/8/2026 8:11:00 AM

Financial Details for ICLR

Company Overview

Ticker ICLR
Company Name Icon Plc
Country USA
Description ICON Public Limited Company (ICLR) is a premier global clinical research organization (CRO) headquartered in Dublin, Ireland, delivering comprehensive outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device sectors. With an established presence in critical markets across Europe and North America, ICON utilizes its deep industry expertise to optimize clinical trial processes, ensure regulatory compliance, and enhance market access strategies, thereby driving efficiencies in drug development. Renowned for its unwavering commitment to innovation and quality, ICON acts as a trusted strategic partner for life sciences companies, facilitating the swift introduction of breakthrough therapies and making significant contributions to the advancement of healthcare.
Sector Name HEALTHCARE
Industry Name DIAGNOSTICS & RESEARCH
Most Recent Quarter 9/30/2025
Next Earnings Date 2/18/2026

Stock Price History

Last Day Price 182.61
Price 4 Years Ago 194.25
Last Day Price Updated 1/16/2026 10:00:40 PM EST
Last Day Volume 1,397,309
Average Daily Volume 937,673
52-Week High 211.00
52-Week Low 125.10
Last Price to 52 Week Low 45.97%

Valuation Measures

Trailing PE 24.87
Industry PE 35.57
Sector PE 54.65
5-Year Average PE 20.98
Free Cash Flow Ratio 29.74
Industry Free Cash Flow Ratio 84.40
Sector Free Cash Flow Ratio 28.78
Current Ratio Most Recent Quarter 1.06
Total Cash Per Share 6.14
Book Value Per Share Most Recent Quarter 122.25
Price to Book Ratio 1.51
Industry Price to Book Ratio 315.68
Sector Price to Book Ratio 43.34
Price to Sales Ratio Twelve Trailing Months 1.77
Industry Price to Sales Ratio Twelve Trailing Months 4.83
Sector Price to Sales Ratio Twelve Trailing Months 19.82
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 76,360,000
Market Capitalization 13,944,099,600
Institutional Ownership 105.78%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -98.70%
Annual Earnings Growth 29.26%
Reported EPS 12 Trailing Months 7.43
Reported EPS Past Year 9.76
Reported EPS Prior Year 14.00
Net Income Twelve Trailing Months 599,476,000
Net Income Past Year 791,474,000
Net Income Prior Year 612,335,000
Quarterly Revenue Growth YOY 0.60%
5-Year Revenue Growth 24.17%
Operating Margin Twelve Trailing Months 12.70%

Balance Sheet

Total Cash Most Recent Quarter 468,888,000
Total Cash Past Year 538,785,000
Total Cash Prior Year 378,102,000
Net Cash Position Most Recent Quarter -2,409,659,000
Net Cash Position Past Year -2,857,613,000
Long Term Debt Past Year 3,396,398,000
Long Term Debt Prior Year 3,665,439,000
Total Debt Most Recent Quarter 2,878,547,000
Equity to Debt Ratio Past Year 0.74
Equity to Debt Ratio Most Recent Quarter 0.76
Total Stockholder Equity Past Year 9,522,999,000
Total Stockholder Equity Prior Year 9,240,743,000
Total Stockholder Equity Most Recent Quarter 9,334,846,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 995,798,650
Free Cash Flow Per Share Twelve Trailing Months 13.04
Free Cash Flow Past Year 1,118,592,000
Free Cash Flow Prior Year 1,020,335,000

Options

Put/Call Ratio 1.26
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.26
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 1/15/2026 10:42:30 PM EST